WDR3

Summary

WDR3 (WD repeat domain 3, HGNC:12755) is a protein-coding gene on chromosome 1p12, encoding WD repeat-containing protein 3 (Q9UNX4). Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. It is a common-essential gene (DepMap: required in 99.3% of cancer cell lines).

This gene encodes a nuclear protein containing 10 WD repeats. WD repeats are approximately 30- to 40-amino acid domains containing several conserved residues, which usually include a trp-asp at the C-terminal end. Proteins belonging to the WD repeat family are involved in a variety of cellular processes, including cell cycle progression, signal transduction, apoptosis, and gene regulation.

Source: NCBI Gene 10885 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 142 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 99.3% of screened cell lines (common-essential)
• MANE Select transcript: NM_006784

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12755
Approved symbol	WDR3
Name	WD repeat domain 3
Location	1p12
Locus type	gene with protein product
Status	Approved
Aliases	FLJ12796, UTP12, DIP2
Ensembl gene	ENSG00000065183
Ensembl biotype	protein_coding
OMIM	604737
Entrez	10885

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 9 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000349139, ENST00000369441, ENST00000471680, ENST00000487202, ENST00000880604, ENST00000880605, ENST00000928994, ENST00000947751, ENST00000947752, ENST00000947753, ENST00000947754

RefSeq mRNA: 1 — MANE Select: NM_006784 NM_006784

CCDS: CCDS898

Canonical transcript exons

ENST00000349139 — 27 exons

Exon	Start	End
ENSE00000785117	117941750	117941847
ENSE00000785118	117942437	117942544
ENSE00000785119	117943396	117943626
ENSE00000785120	117946086	117946179
ENSE00000785121	117948405	117948506
ENSE00000785123	117949751	117949836
ENSE00000785125	117949995	117950130
ENSE00000785127	117950834	117950890
ENSE00000785129	117951976	117952076
ENSE00000785131	117952297	117952408
ENSE00000785132	117952528	117952662
ENSE00000785133	117952946	117952996
ENSE00000785134	117953476	117953541
ENSE00000785135	117954007	117954099
ENSE00000785136	117954580	117954627
ENSE00000785137	117955315	117955358
ENSE00000785138	117957068	117957196
ENSE00000785139	117958910	117959003
ENSE00001195700	117959292	117966543
ENSE00001947224	117929739	117929782
ENSE00003481940	117940827	117940940
ENSE00003509563	117933288	117933490
ENSE00003550321	117939477	117939572
ENSE00003565631	117934473	117934682
ENSE00003588457	117941124	117941225
ENSE00003644484	117936769	117936887
ENSE00003658836	117938480	117938558

Expression profiles

Bgee: expression breadth ubiquitous, 278 present calls, max score 92.44.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.5038 / max 243.7578, expressed in 1750 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
4899	14.0860	1747
4902	0.1957	44
4900	0.1226	50
4901	0.0995	25

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cervix squamous epithelium	UBERON:0006922	92.44	gold quality
squamous epithelium	UBERON:0006914	91.05	gold quality
gingival epithelium	UBERON:0001949	91.00	gold quality
pancreatic ductal cell	CL:0002079	90.78	gold quality
esophagus squamous epithelium	UBERON:0006920	90.55	gold quality
oviduct epithelium	UBERON:0004804	90.47	gold quality
buccal mucosa cell	CL:0002336	90.33	gold quality
parietal pleura	UBERON:0002400	89.77	gold quality
epithelium of esophagus	UBERON:0001976	89.02	gold quality
gingiva	UBERON:0001828	88.69	gold quality
pleura	UBERON:0000977	88.57	gold quality
epithelial cell of pancreas	CL:0000083	88.36	gold quality
germinal epithelium of ovary	UBERON:0001304	88.30	gold quality
islet of Langerhans	UBERON:0000006	88.24	gold quality
visceral pleura	UBERON:0002401	87.45	gold quality
adrenal tissue	UBERON:0018303	87.24	gold quality
choroid plexus epithelium	UBERON:0003911	86.74	gold quality
epithelium of nasopharynx	UBERON:0001951	86.36	gold quality
hair follicle	UBERON:0002073	86.29	gold quality
tibia	UBERON:0000979	85.89	gold quality
ventricular zone	UBERON:0003053	85.82	gold quality
cervix epithelium	UBERON:0004801	85.08	gold quality
ganglionic eminence	UBERON:0004023	85.05	gold quality
amniotic fluid	UBERON:0000173	85.03	gold quality
endothelial cell	CL:0000115	84.75	gold quality
fallopian tube	UBERON:0003889	84.72	gold quality
cartilage tissue	UBERON:0002418	84.54	gold quality
epithelium of mammary gland	UBERON:0003244	84.53	gold quality
cortical plate	UBERON:0005343	84.45	gold quality
nephron tubule	UBERON:0001231	84.39	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.81

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

50 targeting WDR3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-369-3P	99.85	70.52	2264
HSA-MIR-34B-5P	99.78	67.56	1175
HSA-MIR-449C-5P	99.78	67.63	1168
HSA-MIR-5002-5P	99.76	70.84	1763
HSA-MIR-2682-5P	99.73	67.38	1055
HSA-MIR-466	99.67	70.85	2863
HSA-MIR-545-5P	99.66	70.18	2308
HSA-MIR-5700	99.64	69.88	2280
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-7844-5P	99.55	68.56	1428
HSA-MIR-216A-5P	99.50	68.02	1288
HSA-MIR-203A-3P	99.49	70.56	2806
HSA-MIR-3182	99.40	68.15	2454
HSA-MIR-6507-5P	99.36	70.46	2524
HSA-MIR-4727-5P	99.23	67.55	1154
HSA-MIR-4263	99.18	69.25	2236

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.3% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 6)

• WDR3 has an essential function in 40 S ribosomal subunit synthesis and in ribosomal stress signaling to p53-mediated regulation of cell cycle progression in cancer cells (PMID:20392698)
• results indicate for the first time that WDR3 is a risk factor to thyroid cancer, suggesting its implication in the etiology of thyroid cancer (PMID:20578902)
• WDR3 can modulate genome stability in thyroid cancer patients. (PMID:23049746)
• evaluated the genetic association of WDR3 and ALG1 in schizophrenia. We examined 21 single nucleotide polymorphisms [SNPs; W1 (rs1812607)-W16 (rs6656360), A1 (rs8053916)-A10 (rs9673733)] from these genes using the Japanese case-control sample (1,808 schizophrenics and 2,170 matched controls). No significant genetic associations of these SNPs were identified. However, we detected a significant association of W4 (rs319471) (PMID:29309433)
• Overexpressed WDR3 induces the activation of Hippo pathway by interacting with GATA4 in pancreatic cancer. (PMID:33648545)
• WDR3 promotes stem cell-like properties in prostate cancer by inhibiting USF2-mediated transcription of RASSF1A. (PMID:36905106)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	wdr3	ENSDARG00000011079
mus_musculus	Wdr3	ENSMUSG00000033285
rattus_norvegicus	Wdr3	ENSRNOG00000019670
drosophila_melanogaster	CG8064	FBGN0038597

Paralogs (1): TBC1D31 (ENSG00000156787)

Protein

Protein identifiers

WD repeat-containing protein 3 — Q9UNX4 (reviewed: Q9UNX4)

All UniProt accessions (3): Q9UNX4, Q5TDG3, Q6PDA5

UniProt curated annotations — full annotation on UniProt →

Function. Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome.

Subunit / interactions. Part of the small subunit (SSU) processome, composed of more than 70 proteins and the RNA chaperone small nucleolar RNA (snoRNA) U3.

Subcellular location. Nucleus. Nucleolus.

Tissue specificity. Ubiquitous.

Similarity. Belongs to the WD repeat WDR3/UTP12 family.

RefSeq proteins (1): NP_006775* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001680	WD40_rpt	Repeat
IPR007148	SSU_processome_Utp12	Domain
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR019775	WD40_repeat_CS	Conserved_site
IPR020472	WD40_PAC1	Repeat
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily
IPR051570	TBC1_cilium_biogenesis	Family

Pfam: PF04003, PF25172, PF25173

UniProt features (22 total): repeat 13, modified residue 4, cross-link 2, chain 1, region of interest 1, sequence variant 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
7MQA	ELECTRON MICROSCOPY	2.7
7MQ8	ELECTRON MICROSCOPY	3.6
7MQ9	ELECTRON MICROSCOPY	3.87

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UNX4-F1	84.93	0.55

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 240, 241, 257, 726, 474, 529

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-6790901	rRNA modification in the nucleus and cytosol
R-HSA-6791226	Major pathway of rRNA processing in the nucleolus and cytosol

MSigDB gene sets: 141 (showing top): GSE45365_NK_CELL_VS_BCELL_UP, GOBP_RIBOSOME_BIOGENESIS, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GOBP_MATURATION_OF_SSU_RRNA, GOBP_RIBOSOMAL_SMALL_SUBUNIT_BIOGENESIS, GARY_CD5_TARGETS_DN, DODD_NASOPHARYNGEAL_CARCINOMA_UP, chr1p12, ZHANG_BREAST_CANCER_PROGENITORS_UP, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, REACTOME_METABOLISM_OF_RNA, GOCC_90S_PRERIBOSOME, GOCC_PRERIBOSOME, GOCC_SMALL_SUBUNIT_PROCESSOME, GOCC_NUCLEOLUS

GO Biological Process (2): maturation of SSU-rRNA (GO:0030490), ribosomal small subunit biogenesis (GO:0042274)

GO Molecular Function (3): RNA binding (GO:0003723), snoRNA binding (GO:0030515), protein binding (GO:0005515)

GO Cellular Component (6): nucleoplasm (GO:0005654), nucleolus (GO:0005730), nuclear membrane (GO:0031965), small-subunit processome (GO:0032040), Pwp2p-containing subcomplex of 90S preribosome (GO:0034388), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
rRNA processing in the nucleus and cytosol	2

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nuclear lumen	2
nucleolus	2
nuclear protein-containing complex	2
rRNA processing	1
ribosomal small subunit biogenesis	1
ribonucleoprotein complex biogenesis	1
ribosome biogenesis	1
nucleic acid binding	1
RNA binding	1
binding	1
cellular anatomical structure	1
intracellular membraneless organelle	1
nucleus	1
nuclear envelope	1
organelle membrane	1
preribosome	1
t-UTP complex	1
90S preribosome	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

2311 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
WDR3	UTP18	Q9Y5J1	929
WDR3	UTP6	Q9NYH9	910
WDR3	PWP2	Q15269	904
WDR3	TBL3	Q12788	815
WDR3	WDR36	Q8NI36	807
WDR3	UTP4	Q969X6	737
WDR3	HEATR1	Q9H583	712
WDR3	BMS1	Q14692	644
WDR3	GDAP2	Q9NXN4	616
WDR3	BYSL	Q13895	615
WDR3	UTP3	Q9NQZ2	598
WDR3	PWP1	Q13610	598
WDR3	DDB1	Q16531	589
WDR3	NOP14	P78316	572
WDR3	CD34	P28906	549

IntAct

94 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
USP43	YWHAB	psi-mi:“MI:0914”(association)	0.640
C1D	ZFC3H1	psi-mi:“MI:0914”(association)	0.640
EXOSC5	ZFC3H1	psi-mi:“MI:0914”(association)	0.640
NOP53	RRP8	psi-mi:“MI:0914”(association)	0.640
PWP2	FBL	psi-mi:“MI:0914”(association)	0.610
NPM1	MPHOSPH10	psi-mi:“MI:0914”(association)	0.610
ZNF512	ZNF724	psi-mi:“MI:0914”(association)	0.530
RRP8	NVL	psi-mi:“MI:0914”(association)	0.530
N	RBM47	psi-mi:“MI:0914”(association)	0.530
RBM4	NVL	psi-mi:“MI:0914”(association)	0.530
RRP8	MAGEB2	psi-mi:“MI:0914”(association)	0.530
EXOSC4	ZFC3H1	psi-mi:“MI:0914”(association)	0.530
MPHOSPH6	ZFC3H1	psi-mi:“MI:0914”(association)	0.530
ENO4	WDR3	psi-mi:“MI:0915”(physical association)	0.400
WDR3	RPL4	psi-mi:“MI:0915”(physical association)	0.400
Brwd3	WDR91	psi-mi:“MI:0914”(association)	0.350
Rrbp1	PIPSL	psi-mi:“MI:0914”(association)	0.350
NOP56	C12orf43	psi-mi:“MI:0914”(association)	0.350
HNRNPU		psi-mi:“MI:0914”(association)	0.350
EXOSC5	PAPD5	psi-mi:“MI:0914”(association)	0.350
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
RRP1B	ZNF785	psi-mi:“MI:0914”(association)	0.350
MKI67	ARHGAP10	psi-mi:“MI:0914”(association)	0.350
DDX60	G6PD	psi-mi:“MI:0914”(association)	0.350
TCF7L2	LOC401309	psi-mi:“MI:0914”(association)	0.350
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (218): WDR3 (Affinity Capture-MS), WDR3 (Affinity Capture-MS), WDR3 (Affinity Capture-MS), GTPBP4 (Co-fractionation), NSUN5 (Co-fractionation), PUS1 (Co-fractionation), PWP2 (Co-fractionation), RRP9 (Co-fractionation), TBL3 (Co-fractionation), TJP1 (Co-fractionation), WDR3 (Co-fractionation), WDR3 (Co-fractionation), WDR36 (Co-fractionation), WDR3 (Affinity Capture-MS), WDR3 (Proximity Label-MS)

ESM2 similar proteins: A1L112, A4IHS2, A8NZM5, B2ZZS9, O00423, O80775, O95834, P93107, P97452, Q05BC3, Q0DYP5, Q13216, Q13610, Q13685, Q15269, Q1JQD2, Q2HJ56, Q32KQ2, Q32P44, Q3SZK1, Q4V8C3, Q562C2, Q58DT8, Q5BIM8, Q5F3K4, Q5R9T6, Q5RCG7, Q5RFQ3, Q5VU92, Q5XI13, Q5ZK69, Q6DRF9, Q6P6T4, Q6PFM9, Q7TNG5, Q7YR70, Q810D6, Q8BH57, Q8BHB4, Q8BU03

Diamond homologs: A1CF18, B2B766, B2VWG7, B8M0Q1, C5FWH1, C5GVJ9, C5JD40, C5PFX0, C7Z6H2, D4AZ50, D4DG66, O43071, O60508, P38123, P40968, P83774, Q8VYZ5, Q9DC48, Q9UNX4, Q9USN3, A2QP30, B0BNA7, P0CS32, P0CS33, P87177, Q12220, Q13347, Q1HPW4, Q54S79, Q5R7R2, Q8BHB4, Q9C1X1, Q9QZD9, P32479, Q0CQ54, Q10282, Q6CB13, Q6ZMW3, Q08924, Q7KWL3

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
WDR3	“form complex”	“UTP-B complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 126 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Nuclear RNA decay	5	18.8×	7e-04
rRNA modification in the nucleus and cytosol	6	13.7×	7e-04
rRNA processing in the nucleus and cytosol	6	11.8×	1e-03
Major pathway of rRNA processing in the nucleolus and cytosol	15	11.3×	1e-09
rRNA processing	6	10.7×	2e-03
SARS-CoV-1-host interactions	5	10.7×	3e-03
Peptide chain elongation	6	9.3×	2e-03
Viral mRNA Translation	6	9.3×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
ribosomal large subunit biogenesis	6	24.4×	3e-05
ribosomal small subunit biogenesis	10	20.9×	2e-08
rRNA processing	13	16.9×	5e-10
regulation of alternative mRNA splicing, via spliceosome	6	13.4×	6e-04
RNA processing	6	12.1×	9e-04
cytoplasmic translation	7	11.9×	3e-04
RNA splicing	10	8.1×	8e-05
translation	8	7.5×	9e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

142 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	109
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

4018 predictions. Top by Δscore:

Variant	Effect	Δscore
1:117929420:C:A	donor_gain	1.0000
1:117929433:AGTC:A	donor_gain	1.0000
1:117929436:C:A	donor_gain	1.0000
1:117929439:T:TA	donor_gain	1.0000
1:117929446:A:AC	donor_gain	1.0000
1:117929447:C:CC	donor_gain	1.0000
1:117929447:CAGCA:C	donor_gain	1.0000
1:117929452:CT:C	donor_gain	1.0000
1:117933282:GCACA:G	acceptor_loss	1.0000
1:117933283:CACA:C	acceptor_loss	1.0000
1:117933284:ACAGA:A	acceptor_loss	1.0000
1:117933285:CA:C	acceptor_loss	1.0000
1:117933286:A:AG	acceptor_gain	1.0000
1:117933286:A:C	acceptor_loss	1.0000
1:117933286:AGATT:A	acceptor_gain	1.0000
1:117933287:G:GC	acceptor_loss	1.0000
1:117933287:G:GG	acceptor_gain	1.0000
1:117933287:GAT:G	acceptor_gain	1.0000
1:117933287:GATT:G	acceptor_gain	1.0000
1:117933287:GATTG:G	acceptor_gain	1.0000
1:117936764:TTTA:T	acceptor_loss	1.0000
1:117936765:TTA:T	acceptor_loss	1.0000
1:117936884:CTAGG:C	donor_loss	1.0000
1:117936885:TAGG:T	donor_loss	1.0000
1:117936886:AGGT:A	donor_loss	1.0000
1:117936887:GG:G	donor_loss	1.0000
1:117936888:G:T	donor_loss	1.0000
1:117936889:T:A	donor_loss	1.0000
1:117938476:TTA:T	acceptor_loss	1.0000
1:117938478:A:AG	acceptor_gain	1.0000

AlphaMissense

6216 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:117943619:T:A	W441R	1.000
1:117943619:T:C	W441R	1.000
1:117933467:T:A	W50R	0.999
1:117933467:T:C	W50R	0.999
1:117936787:T:A	W134R	0.999
1:117936787:T:C	W134R	0.999
1:117949785:T:A	V520D	0.999
1:117952024:T:A	W618R	0.999
1:117952024:T:C	W618R	0.999
1:117952370:T:A	W660R	0.999
1:117952370:T:C	W660R	0.999
1:117933438:C:A	A40E	0.998
1:117938505:T:A	W176R	0.998
1:117938505:T:C	W176R	0.998
1:117939541:T:C	L215P	0.998
1:117943568:A:C	S424R	0.998
1:117943570:C:A	S424R	0.998
1:117943570:C:G	S424R	0.998
1:117943592:T:C	S432P	0.998
1:117943620:G:C	W441S	0.998
1:117943621:G:C	W441C	0.998
1:117943621:G:T	W441C	0.998
1:117946106:G:C	R450P	0.998
1:117946172:G:A	G472E	0.998
1:117949793:T:A	W523R	0.998
1:117949793:T:C	W523R	0.998
1:117951998:G:A	G609D	0.998
1:117952000:T:C	S610P	0.998
1:117952006:G:C	D612H	0.998
1:117952026:G:C	W618C	0.998

dbSNP variants (sampled 300 via entrez): RS1000157818 (1:117933486 A>G), RS1000241479 (1:117960230 C>G), RS1000371551 (1:117932148 C>G), RS1000539723 (1:117965727 G>T), RS1000572569 (1:117953189 CA>C), RS1000724784 (1:117945800 T>C), RS1000857027 (1:117958754 G>A), RS1001270805 (1:117932842 C>G), RS1001321766 (1:117933060 C>T), RS1001330214 (1:117951249 G>T), RS1001337339 (1:117947056 A>G), RS1001339277 (1:117952020 A>G), RS1001427895 (1:117960158 GTATGTA>G), RS1001571737 (1:117966356 T>C), RS1001584452 (1:117932587 CCTGT>C)

Disease associations

OMIM: gene MIM:604737 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST012442_45	Age-related hearing impairment	3.000000e-09

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5725055 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.00	IC50	100	nM	MOLIBRESIB

PubChem BioAssay actives

1 with measured affinity, of 6 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2178554: Inhibition of WDR3 (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	0.1000	uM

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, increases expression, decreases expression, affects cotreatment	3
Cadmium Chloride	decreases expression, increases abundance, increases expression	3
Benzo(a)pyrene	decreases expression, affects methylation	2
Estradiol	increases expression	2
FR900359	decreases phosphorylation	1
dicrotophos	decreases expression	1
alpha phellandrene	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
deoxynivalenol	increases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
coumarin	increases phosphorylation	1
azoxystrobin	decreases expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	increases expression	1
pyrachlostrobin	decreases expression	1
picoxystrobin	decreases expression	1
Resveratrol	increases expression, affects cotreatment	1
Acetaminophen	decreases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Cadmium	increases abundance, increases expression	1
Caffeine	decreases phosphorylation	1
Cisplatin	decreases expression	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Diazinon	increases methylation	1
Ethyl Methanesulfonate	decreases expression	1
Folic Acid	decreases expression	1
Formaldehyde	decreases expression	1
Hydrogen Peroxide	affects expression	1
Ivermectin	decreases expression	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5697284	Binding	Inhibition of WDR3 (unknown origin) assessed as fold change at 10 uM incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. — Nature

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.